BTIG has initiated coverage of BioAge Labs with a buy rating and a price target of $40, suggesting a potential upside of 120% from the stock's closing price on Tuesday. Analyst Thomas Shrader highlighted BioAge's unique approach to drug development, particularly its focus on aging and chronic inflammation, supported by a proprietary dataset.
He identified BGE-102, an oral therapy aimed at age-related inflammation, as a key driver of the company's value, with expected updates on its clinical trial efficacy in the latter half of this year likely to positively impact the stock.
Additionally, the newer drug BGE-105 is noted for its strong synergy with GLP-1 weight loss drugs, with further data anticipated in mid-2027, which could also act as a catalyst for share price growth. This optimistic outlook aligns with the broader consensus on Wall Street, where five out of seven analysts recommend buying the stock.
BioAge shares have already increased by 38% this year, outperforming the overall market